Nirsevimab Injection (Beyfortus) – RSV Protection for Infants | 50 mg & 100 mg

Protect your baby from Respiratory Syncytial Virus (RSV) with Nirsevimab (brand name: Beyfortus), a long-acting monoclonal antibody approved for the prevention of serious RSV infections in newborns and infants. Specially designed for single-dose protection throughout the RSV season, Nirsevimab is a breakthrough in pediatric care.

✅ Highly Effective RSV Prevention
✅ Single Dose Protection for Entire RSV Season
✅ Recommended for Infants & High-Risk Toddlers
✅ Available in 50 mg & 100 mg Pre-filled Syringes
✅ Globally Approved (FDA, EMA, etc.)

Indication:

For the prevention of serious lower respiratory tract disease caused by RSV in:
– Newborns and infants during their first RSV season
– Children up to 24 months at increased risk during their second RSV season

Dosage Options:

• 50 mg IM for infants under 5 kg

• 100 mg IM for infants 5 kg or more

• 200 mg (2 x 100 mg) for children entering second RSV season

Storage:
Keep refrigerated (2°C–8°C). Do not freeze. Protect from light.